Unicycive Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net loss per share

Net loss per share

3 Months Ended

Mar. 31, 2022

11. Net loss per share

The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):

	Three Months Ended March 31,
	2021			2022
Numerator:
Net loss	$	(964	)	$	(3,537	)

Denominator:
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted		8,576,422			15,004,617
Net loss per share attributable to common stockholders, basic and diluted	$	(0.11	)	$	(0.24	)

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:

	Three Months Ended March 31,
	2021		2022

Options to purchase common stock		684,322		1,187,085
Warrants to purchase common stock		-		4,784,193
Total		684,322		5,971,278